TNFRSF4 and non-small cell lung carcinoma: Numerous clinical trials are exploring the application of co-stimulatory anti-OX40 mAbs as adjuvants in combination with chemotherapy, radiotherapy, and PD-L1 blockade in patients with advanced solid neoplasms, with OX40-expressing TILs correlating with better outcomes in NSCLC patients.